Operating Leverage Inflection
Expected: CurrentHIGH confidence
What: Employee cost leverage: 450 bps
Impact: PAT up 86%
“This expansion is mainly due to operating leverage on employee costs of approximately 450 bps and material margin of 100 bps.”
Sai Life Sciences Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +22.6%Weak7w Streak
In , Sai Life Sciences Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +22.6% relative strength. Fundamentals: Weak. On a 7-week streak.
Sai Life Sciences Ltd Key Facts
- PE Ratio
- 65.1x
- Market Cap
- ₹23,103 Cr
- PAT Growth YoY
- +18%
- Revenue Growth YoY
- +4%
- OPM
- 29.0%
- RS vs Nifty 500
- +22.6%
Emerging Opportunity
What's Happening
⏳Steady earner with flat PE — waiting for re-rate catalyst
📊Debt increased 45% YoY — leverage rising
🌐FII stake increased 1.3% this quarter
🏛️DII reducing — stake down 1.6%
💰Trading 12% above estimated fair value
Earnings Acceleration Triggers
1. Operating Leverage Inflection
CurrentHIGH
2. Geographical Expansion
Multi-year journeyHIGH
3. New Product Or Brand Launch
FY26 YTDMEDIUM
Key Risks
1. The Biosecure Act and potential tariffs on pharma intermediates
MEDIUM2. Supply chain concentration in single geographies (China)
LOW3. Need for high-quality talent and potential wage inflation as the company scales
LOWSector-Specific Signals
CDMO Revenue Share65%+1%
CRO Revenue Share35%-1%
Late-Phase/Commercial Pipeline Additions7 molecules
Top Customer Concentration12%Inline
Key Numbers
PAT Growth YoY
+18%
Stable
Revenue YoY
+4%
Decelerating
Operating Margin
29.0%
+200 bps YoY
PE Ratio
65.1
Current Price
₹1,091
Fundamental Score
34/100
Weak
3Y PAT CAGR
+80%
Market Cap
23.1K Cr
Valuation
Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Sai Life Sciences Ltd's Earnings Accelerating?
Based on Q3 FY26 earnings • Updated Apr 18, 2026
Geographical Expansion
Expected: Multi-year journeyHIGH confidence
What: China+1 supply chain rebalancing: Not Given
“Our experience based on multiple conversations that we have been having with pharma innovators is that the companies are definitely seeking to rebalance their global supply chain.”
New Product Or Brand Launch
Expected: FY26 YTDMEDIUM confidence
What: Late-phase/Commercial pipeline additions: 7 molecules
“During the year, we added 7 molecules to our late-phase and commercial pipeline, further broadening our portfolio.”
Value Added Product Mix Shift
Expected: FY27MEDIUM confidence
What: New modalities (Peptides, ADCs, Oligos): Not Given
“This expenditure was primarily focused on expanding our R&D infrastructure... and advancing investments in new modalities and technologies such as peptides, ADCs, and oligonucleotides.”
Client Mining Cross Selling Wallet Share
Expected: OngoingLOW confidence
What: Large pharma revenue share: 90% of CDMO
“Our CDMO business continues to perform well with over 90% of revenues coming from large pharma customers.”
EBITDA Margin of 34% vs 28-30% guidance
HIGH confidence
What: EBITDA Margin of 34% vs 28-30% guidance
“This expansion is mainly due to operating leverage on employee costs of approximately 450 bps and material margin of 100 bps.”
What Are the Key Risks for Sai Life Sciences Ltd?
Earnings deceleration risks from management commentary
The Biosecure Act and potential tariffs on pharma intermediates
MEDIUMTrigger: Geopolitical tensions and US policy changes regarding sourcing from China.
Management view: Management believes most pharmas have exemptions and that India serves as a tactical backup or second source.
Monitor: regulatory
Supply chain concentration in single geographies (China)
LOWTrigger: Major events over the last few years uncovered risks associated with concentration.
Management view: Diversifying the portfolio and supply chain to mitigate the impact of geopolitical ups and downs.
Monitor: geopolitical
Need for high-quality talent and potential wage inflation as the company scales
LOWTrigger: Scaling operations requires augmenting the talent base to support initiatives.
Management view: Focusing on transformation programs to improve productivity and operating efficiency.
Monitor: labor
What Is Sai Life Sciences Ltd's Management Saying?
Key quotes from recent conference calls
“We are not giving a specific guidance on where the gross margins are, but what we have given guidance is the 28% - 30% EBITDA. [Previous EBITDA Margin guidance]”
“we continue to remain confident of meeting the 15%-20% revenue growth over a 3-5 period. [Previous Revenue Growth guidance]”
“We intend to add 225 KL by June and another 225 KL by the fourth quarter of FY ‘27, almost increasing our capacity by 70% in manufacturing. [Initiative: Capacity Expansion (Bidar)]”
“we are working with an external consulting firm to define AI first roadmap... we expect increasing automation to allow our scientists to spend more time on high-value science. [Initiative: AI-First Roadmap]”
What Did Sai Life Sciences Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
INR 556 crores
YoY +27%
Why: Growth was broad-based across the portfolio with the CDMO business contributing approximately 65% of the revenues and the CRO business contributing the remaining 35%.
Revenue growth outpaced broader industry trends supported by a robust commercial pipeline.
EBITDA
INR 191 crores
YoY +54%Margin 34%
Why: Expansion is mainly due to operating leverage on employee costs of approximately 450 bps and material margin of 100 bps.
EBITDA margin of 34% is currently ahead of the stated long-term goal of 28% to 30%.
PAT
INR 100 crores
YoY +86%
Why: The increase was driven by healthy revenue growth, strong EBITDA expansion with meaningful margin accretion, and robust improvement in profitability.
PAT growth significantly outpaced revenue growth due to high operating leverage.
Other Highlights
• CDMO revenues grew by around 31% while CRO revenues increased by approximately 19% year-on-year.
• Nine-month fiscal ‘26 EBITDA stood at 30%, achieving the stated goal ahead of schedule.
• Current capacity utilization stands at around 60%, providing headroom for growth.
What Sector Metrics Matter for Sai Life Sciences Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
CDMO Revenue Share
65%
YoY +1%
Why: Driven by a continuous scale-up of late-stage and commercial programs.
CRO Revenue Share
35%
YoY -1%
Why: Reflects sustained engagement with both large pharma and biotech firms, though growing slower than CDMO.
Late-Phase/Commercial Pipeline Additions
7 molecules
Why: Broadening the portfolio to enhance business resilience.
Top Customer Concentration
12%
YoY Inline
Why: Management aims to keep the portfolio broad to mitigate destocking risks.
Capacity Utilization
60%
Why: Provides adequate headroom for growth even ahead of new capacities coming on stream.
Total Installed Capacity
700 KL
Why: Base capacity before the planned expansion to 1150 KL.
Employee Cost Operating Leverage
450 bps
Why: Result of upfronted R&D people costs being absorbed as the business grows.
Material Margin Improvement
100 bps
Why: Driven by product mix and process efficiencies gained on certain commercial products.
Customer Audits (Last 12 Months)
35
Why: Reflects strong operational discipline and commitment to global regulatory excellence.
Regulatory Audits with Zero Observations
3
Why: Maintained highest standards of quality and compliance.
What Is Sai Life Sciences Ltd's Management Guidance?
Forward-looking targets from management for 3-5 years
Revenue Growth Target
15%
OPM Guidance
28–30%
Capex Plan
₹700 Cr
Revenue Outlook
15% to 20%
Margin Outlook
REAFFIRMED
Capex Plan
INR 700 crores
Expanding R&D infrastructure, process development capabilities, and new modalities like peptides and ADCs.
Management Tone: BULLISH
Guidance Changes
REAFFIRMED
EBITDA Margin: 28% - 30% → 28% - 30%
How Fast Is Sai Life Sciences Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +4% | +22% | Decelerating |
| PAT (Net Profit) | +18% | +80% | Stable |
| OPM | 29.0% | +200 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Other Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Sai Life Sciences Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Sai Life Sciences Ltd's latest quarterly results?
Sai Life Sciences Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +18.2% (stable)
- Revenue Growth YoY: +3.8%
- Operating Margin: 29.0% (volatile)
Is Sai Life Sciences Ltd's profit growing or declining?
Sai Life Sciences Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +18.2% (latest quarter)
- PAT Growth QoQ: +4.0% (sequential)
- 3-Year PAT CAGR: +80.0%
- Trend: Stable — consistent growth pattern
What is Sai Life Sciences Ltd's revenue growth trend?
Sai Life Sciences Ltd's revenue growth trend is decelerating.
- Revenue Growth YoY: +3.8%
- Revenue Growth QoQ: +8.3% (sequential)
- 3-Year Revenue CAGR: +21.7%
How is Sai Life Sciences Ltd's operating margin trending?
Sai Life Sciences Ltd's operating margin is volatile.
- Current OPM: 29.0%
- OPM Change YoY: +2.0% basis points
- OPM Change QoQ: -5.0% basis points
What is Sai Life Sciences Ltd's 3-year profit and revenue CAGR?
Sai Life Sciences Ltd's long-term compounding rates
- 3-Year Profit CAGR: +80.0%
- 3-Year Revenue CAGR: +21.7%
Is Sai Life Sciences Ltd's growth accelerating or decelerating?
Sai Life Sciences Ltd's earnings growth is stable with positive momentum on a sequential basis.
- YoY Acceleration: -67.0% bps
- Sequential Acceleration: -15.0% bps
What is Sai Life Sciences Ltd's trailing twelve month (TTM) performance?
Sai Life Sciences Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹348 Cr
- TTM PAT Growth: +100.0% YoY
- TTM Revenue: ₹2,000 Cr
- TTM Revenue Growth: +29.2% YoY
- TTM Operating Margin: 28.6%
Is Sai Life Sciences Ltd overvalued or undervalued?
Sai Life Sciences Ltd appears overvalued based on our fair value analysis.
- Valuation Signal: Overvalued
- Current PE: 65.1x
- Price-to-Book: 9.3x
What is Sai Life Sciences Ltd's current PE ratio?
Sai Life Sciences Ltd's current PE ratio is 65.1x.
- Current PE: 65.1x
- Market Cap: 23.1K Cr
How does Sai Life Sciences Ltd's valuation compare to its history?
Sai Life Sciences Ltd's current PE is 65.1x.
- Current PE: 65.1x
- Valuation Assessment: Overvalued
What is Sai Life Sciences Ltd's price-to-book ratio?
Sai Life Sciences Ltd's price-to-book ratio is 9.3x.
- Price-to-Book (P/B): 9.3x
- Book Value per Share: ₹117
- Current Price: ₹1091
Is Sai Life Sciences Ltd a fundamentally strong company?
Sai Life Sciences Ltd is rated Weak with a fundamental score of 34.4/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +3.8% (10% weight)
- PAT Growth YoY: +18.2% (10% weight)
- PAT Growth QoQ: +4.0% (10% weight)
- Margins stable (10% weight)
Is Sai Life Sciences Ltd debt free?
Sai Life Sciences Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹288 Cr
What is Sai Life Sciences Ltd's return on equity (ROE) and ROCE?
Sai Life Sciences Ltd's return ratios over recent years
- FY2024: ROCE 11.0%
- FY2025: ROCE 14.0%
- FY2026: ROCE 20.0%
Is Sai Life Sciences Ltd's cash flow positive?
Sai Life Sciences Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹314 Cr
- Free Cash Flow (FCF): ₹-222 Cr
- CFO/PAT Ratio: 185% (strong cash conversion)
What is Sai Life Sciences Ltd's dividend yield?
Sai Life Sciences Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹1091
Who holds Sai Life Sciences Ltd shares — promoters, FII, DII?
Sai Life Sciences Ltd's shareholding pattern (Mar 2026)
- Promoters: 34.6%
- FII (Foreign): 21.2%
- DII (Domestic): 31.5%
- Public: 12.7%
Is promoter holding increasing or decreasing in Sai Life Sciences Ltd?
Sai Life Sciences Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 34.6% (Mar 2026)
- Previous Quarter: 34.7% (Dec 2025)
- Change: -0.09% (decreasing — worth monitoring)
How long has Sai Life Sciences Ltd been outperforming Nifty 500?
Sai Life Sciences Ltd has been outperforming Nifty 500 for 7 consecutive weeks, indicating building momentum.
Is Sai Life Sciences Ltd a new momentum entry or an established outperformer?
Sai Life Sciences Ltd is an established outperformer with 7 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Sai Life Sciences Ltd?
Sai Life Sciences Ltd has 6 key growth catalysts identified from recent earnings analysis
- Operating Leverage Inflection — Upfronted R&D and people costs are now being absorbed by higher revenue volumes.
- Geographical Expansion — Pharma innovators are seeking to rebalance global supply chains away from single-geography concentration.
- New Product Or Brand Launch — Broadening the portfolio with commercial molecules enhances business resilience and offsets volume variability.
- Value Added Product Mix Shift — Deepening capabilities in complex therapeutics to support the next wave of innovator needs.
What are the key risks in Sai Life Sciences Ltd?
Sai Life Sciences Ltd has 3 key risks worth monitoring
- [MEDIUM] The Biosecure Act and potential tariffs on pharma intermediates — Geopolitical tensions and US policy changes regarding sourcing from China.
- [LOW] Supply chain concentration in single geographies (China) — Major events over the last few years uncovered risks associated with concentration.
- [LOW] Need for high-quality talent and potential wage inflation as the company scales — Scaling operations requires augmenting the talent base to support initiatives.
What did Sai Life Sciences Ltd's management say in the latest earnings call?
In Q3 FY26, Sai Life Sciences Ltd's management highlighted
- "We are not giving a specific guidance on where the gross margins are, but what we have given guidance is the 28% - 30% EBITDA. [Previous EBITDA Margi..."
- "we continue to remain confident of meeting the 15%-20% revenue growth over a 3-5 period. [Previous Revenue Growth guidance]"
- "We intend to add 225 KL by June and another 225 KL by the fourth quarter of FY ‘27, almost increasing our capacity by 70% in manufacturing. [Initiati..."
What is Sai Life Sciences Ltd's management guidance for growth?
Sai Life Sciences Ltd's management has provided the following forward guidance for 3-5 years
- Revenue growth target: 15%
- OPM guidance: 28–30%
- Capex plan: ₹700 Cr for Expanding R&D infrastructure, process development capabilities, and new modalities like peptides and ADCs.
- Management tone: bullish
- Milestone: [REAFFIRMED] EBITDA Margin: 28% - 30% → 28% - 30%
What sector-specific metrics matter most for Sai Life Sciences Ltd?
Sai Life Sciences Ltd's most important sub-sector-specific KPIs from the latest concall
- CDMO Revenue Share: 65% (YoY +1%) — Driven by a continuous scale-up of late-stage and commercial programs.
- CRO Revenue Share: 35% (YoY -1%) — Reflects sustained engagement with both large pharma and biotech firms, though growing slower than CDMO.
- Late-Phase/Commercial Pipeline Additions: 7 molecules — Broadening the portfolio to enhance business resilience.
- Top Customer Concentration: 12% (YoY Inline) — Management aims to keep the portfolio broad to mitigate destocking risks.
- Capacity Utilization: 60% — Provides adequate headroom for growth even ahead of new capacities coming on stream.
- Total Installed Capacity: 700 KL — Base capacity before the planned expansion to 1150 KL.
Is Sai Life Sciences Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Sai Life Sciences Ltd may be worth studying
- Earnings growing at +18.2% YoY
- Cash flow is positive — CFO ₹314 Cr
What is the investment thesis for Sai Life Sciences Ltd?
Sai Life Sciences Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Operating Leverage Inflection
Risk Factors (Bear Case)
- Appears overvalued
- Key risk: The Biosecure Act and potential tariffs on pharma intermediates
What is the future outlook for Sai Life Sciences Ltd?
Sai Life Sciences Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: decelerating
- Margin Trend: volatile
- Valuation: Overvalued
- Key Catalyst: Operating Leverage Inflection
- Key Risk: The Biosecure Act and potential tariffs on pharma intermediates
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.